India Globalization Capital Inc
$ 0.34
4.64%
17 Apr - close price
- Market Cap 31,713,500 USD
- Current Price $ 0.34
- High / Low $ 0.34 / 0.32
- Stock P/E N/A
- Book Value 0.09
- EPS -0.06
- Next Earning Report 2026-06-15
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.83 %
- 52 Week High 0.50
- 52 Week Low 0.24
About
India Globalization Capital, Inc. buys and resells physical infrastructure commodities. The company is headquartered in Potomac, Maryland.
Analyst Target Price
$4.12
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-18 | 2025-11-17 | 2025-08-05 | 2025-06-30 | 2025-02-12 | 2024-11-07 | 2024-08-07 | 2024-06-24 | 2024-02-14 | 2023-11-09 | 2023-08-10 | 2023-06-30 |
| Reported EPS | -0.02 | -0.02 | -0.0148 | -0.02 | -0.02 | -0.02 | -0.03 | -0.4 | -0.09 | -0.05 | -0.04 | -0.0759 |
| Estimated EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 | -0.05 | 0 | None |
| Surprise | 0 | 0 | 0.0152 | 0 | 0.01 | 0.01 | 0 | -0.36 | -0.05 | 0 | -0.04 | 0 |
| Surprise Percentage | 0% | 0% | 50.6667% | 0% | 33.3333% | 33.3333% | 0% | -900% | -125% | 0% | None% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-06-15 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.025 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IGC
2026-04-14 14:39:28
IGC Pharma announced it has reached 80% patient enrollment in its Phase 2 CALMA clinical trial for IGC-AD1, which targets agitation associated with Alzheimer's disease. The company anticipates completing enrollment by mid-2026, followed by database lock and topline results. This milestone positions IGC Pharma to potentially bring a new treatment to a largely underserved market for Alzheimer's patients experiencing agitation.
2026-04-14 12:40:23
IGC Pharma announced 80% patient enrollment in its Phase 2 CALMA clinical trial for IGC-AD1, targeting agitation associated with Alzheimer's disease. This milestone positions the company for enrollment completion by mid-2026 and subsequent data readout. CEO Ram Mukunda highlighted the significance of this progress towards addressing a largely underserved market for Alzheimer's agitation treatment.
2026-04-14 12:39:28
IGC Pharma announced that its Phase 2 CALMA trial for IGC-AD1, targeting agitation in Alzheimer's disease, has reached approximately 80% enrollment. The company anticipates completing enrollment by mid-2026, positioning it for database lock and the release of topline results. This milestone is a significant step towards a potential new treatment option in a market with considerable unmet need.
2026-04-14 12:39:28
IGC Pharma has announced 80% patient enrollment in its Phase 2 CALMA clinical trial for IGC-AD1, targeting agitation in Alzheimer's disease. This milestone positions the company for enrollment completion by mid-2026 and subsequent data readout, addressing a significant unmet medical need in a multi-billion dollar market. IGC-AD1 is an investigational therapy designed to assess both safety and efficacy in patients experiencing agitation associated with Alzheimer's.
2026-04-12 20:09:01
This article reports that the price target for IGC Pharma (IGC) has been increased by 10.34% to 4.08. No further details are available in the provided content.
2026-04-11 14:10:31
New to The Street will broadcast a new episode tonight at 6:30 PM EST on Bloomberg Television, featuring executive interviews and company insights from IGC Pharma, Vivos Therapeutics, Acurx Pharmaceuticals, and Equinox Gold. The broadcast also includes a continuing M&A segment with Frank Aquila from Sullivan & Cromwell LLP. New to The Street distinguishes itself with national television exposure, a large YouTube audience, and prominent outdoor billboard placements in Times Square and the New York Financial District.
